Clinuvel Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Clinuvel Pharmaceuticals (ASX:CUV) Full Year 2024 Results

Key Financial Results

• Revenue: AU$88.2m (up 13% from FY 2023).
• Net income: AU$35.6m (up 16% from FY 2023).
• Profit margin: 40% (up from 39% in FY 2023). The increase in margin was driven by higher revenue.
• EPS: AU$0.71 (up from AU$0.62 in FY 2023).

CUV Products In Clinical Trials

• Phase II: 6.
• Phase III: 2.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Clinuvel Pharmaceuticals Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 4.3%.

The primary driver behind last 12 months revenue was the Europe & USA Excl. Switzerland segment contributing a total revenue of AU$81.5m (92% of total revenue). The largest operating expense was General & Administrative costs, amounting to AU$28.9m (65% of total expenses). Explore how CUV's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Biotechs industry in Australia.

Performance of the Australian Biotechs industry.

The company's shares are up 16% from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with Clinuvel Pharmaceuticals.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.